NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study

Movement Disorders : Official Journal of the Movement Disorder Society
Christopher F O'BrienJulio C Castro-Gayol

Abstract

Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor. We present results of a randomized, 6-week, double-blind, placebo-controlled, dose-titration study evaluating the safety, tolerability, and efficacy of NBI-98854 for the treatment of tardive dyskinesia. Male and female adult subjects with moderate or severe tardive dyskinesia were included. NBI-98854 or placebo was given once per day starting at 25 mg and then escalated by 25 mg to a maximum of 75 mg based on dyskinesia and tolerability assessment. The primary efficacy endpoint was the change in Abnormal Involuntary Movement Scale from baseline at week 6 scored by blinded, central video raters. The secondary endpoint was the Clinical Global Impression of Change-Tardive Dyskinesia score assessed by the blinded investigator. Two hundred five potential subjects were screened, and 102 were randomized; 76% of NBI-98854 subjects and 80% of placebo subjects reached the maximum allowed dose. Abnormal Involuntary Movement Scale scores for NBI-98854 compared with placebo were significantly reduced (p = 0.0005). Active drug was also superior on the Clinical Globa...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jul 1, 1990·Schizophrenia Research·D AddingtonB Schissel
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Movement Disorders : Official Journal of the Movement Disorder Society·M R SamieS Rozek
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1997·Schizophrenia Bulletin·M F EganR J Wyatt
Aug 8, 2007·Archives of General Psychiatry·Dilip V JesteHelena C Kraemer
Mar 4, 2008·The Journal of Clinical Psychiatry·Scott W WoodsCenk Tek
Mar 12, 2008·Current Opinion in Psychiatry·Christoph U Correll, Eva M Schenk
Mar 3, 2011·Current Treatment Options in Neurology·Pratibha G AiaStewart A Factor
Jan 9, 2014·Neurochemistry International·Alison I BernsteinGary W Miller

❮ Previous
Next ❯

Citations

Mar 31, 2016·International Journal of Clinical Practice·L Citrome
Apr 20, 2016·Drugs·Dhanya Vijayakumar, Joseph Jankovic
Aug 16, 2016·The Psychiatric Clinics of North America·Stanley N Caroff, E Cabrina Campbell
Nov 5, 2016·Parkinsonism & Related Disorders·Jaime M Hatcher-MartinStewart A Factor
Apr 28, 2018·Nature Reviews. Drug Discovery·Jarkko RautioMichael J Hageman
May 9, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Karl KieburtzC Warren Olanow
Oct 4, 2017·Expert Review of Neurotherapeutics·Thomas Müller
Oct 3, 2017·Journal of Comparative Effectiveness Research·Stanley N CaroffCharles Yonan
Feb 7, 2019·Neurodegenerative Disease Management·Natalie Witek, Cynthia Comella
Mar 15, 2019·Clinical Neuropharmacology·Nicki Niemann, Joseph Jankovic
Jun 25, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Mark StacyChristoph U Correll
Apr 14, 2017·The Journal of Pharmacology and Experimental Therapeutics·Dimitri E GrigoriadisHaig Bozigian
Feb 20, 2018·Journal of Pharmacy Practice·Alyssa M Peckham, Jessica A Nicewonder
Jan 18, 2018·Expert Review of Clinical Pharmacology·Harini Sarva, Claire Henchcliffe
Oct 17, 2019·International Journal of Geriatric Psychiatry·Martha SajatovicScott Siegert
Nov 7, 2019·Journal of Clinical Psychopharmacology·Stephen R MarderChristopher F OʼBrien
Oct 16, 2019·Expert Opinion on Pharmacotherapy·Daniel O ClaassenBenjamin Carroll
Dec 1, 2017·Neurology. Clinical Practice·Davide Martino, Francesca Morgante
May 19, 2020·CNS Spectrums·Jean-Pierre LindenmayerChristopher F O'Brien
Sep 5, 2019·CNS Spectrums·Mazen T Elkurd, Laxman Bahroo
Jul 7, 2020·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Pierre J Blanchet
Jul 21, 2017·Expert Review of Neurotherapeutics·Stanley N CaroffBenjamin Carroll
Jul 13, 2017·Expert Opinion on Pharmacotherapy·Lauren C Seeberger, Robert A Hauser
Nov 8, 2016·Expert Opinion on Pharmacotherapy·Joseph Jankovic
Feb 23, 2019·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Lucia RicciardiMark Edwards
Jul 29, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stewart A Factor
Aug 30, 2019·Journal of Comparative Effectiveness Research·Saurabh AggarwalChuck Yonan
Jun 18, 2019·Therapeutic Advances in Psychopharmacology·Rikinkumar S PatelMuhammad Khalid Zafar
Oct 31, 2019·Expert Opinion on Pharmacotherapy·Laszlo SzpisjakLaszlo Vecsei
Dec 9, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Dao Thai-CuartoJoshua Burke
Mar 20, 2018·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserHanna Bergman
Jun 5, 2017·Drugs·Esther S Kim
Sep 2, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jason M Noel, Cherry W Jackson
Oct 24, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ian O BledsoeMarta San Luciano
Oct 31, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Stanley N Caroff
Sep 22, 2020·Journal of the Chinese Medical Association : JCMA·Chun-Yu ChenJong-Ling Fuh
Jan 5, 2021·Journal of Medical Economics·Michael L GanzCharles Yonan
Dec 26, 2018·Journal of Affective Disorders·Roger S McIntyreJoshua Burke
Jul 8, 2019·Lancet Neurology·Stewart A FactorCynthia L Comella
Jan 9, 2021·Case Reports in Psychiatry·Robert O MortonRissa Fedora

❮ Previous
Next ❯

Methods Mentioned

BETA
Sedation

Clinical Trials Mentioned

NCT01733121

Software Mentioned

Interactive Web Response System ( IWRS )

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
Rajesh PahwaMary Jean Stempien
Movement Disorders : Official Journal of the Movement Disorder Society
Daniela BergBaltazar Gomez-Mancilla
Movement Disorders : Official Journal of the Movement Disorder Society
Joaquim J FerreiraBernhard Landwehrmeyer
The American Journal of Psychiatry
A M ElkashefD Barrett
© 2021 Meta ULC. All rights reserved